Nuvig Therapeutics

Nuvig Therapeutics is a clinical-stage biotech in the San Francisco Bay Area developing next-generation immune modulators for chronic autoimmune and inflammatory diseases. Founded in 2022 on research from The Rockefeller University, its lead candidate NVG-2089 is a first-in-class recombinant Fc fragment that engages type II Fc receptors to recapitulate the anti-inflammatory benefits of IVIg without immunosuppression or the supply constraints of plasma-derived products. The company raised a $161M Series B in December 2024 to push NVG-2089 into Phase 2 for CIDP and other indications.